Remeron

Quick links to important sections

Remeron

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Remeron

Property Description
Active ingredient Mirtazapine
Form Tablet, Oral Disintegrating Tablet (ODT)
Pharmacological class Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)
General therapeutic purpose Support for balanced mood and emotional stability
Origin Synthetic compound

The Core Identity of Mirtazapine: A Noradrenergic and Specific Serotonergic Antidepressant

Remeron is the established trade name for the active ingredient, Mirtazapine (INN), a synthetic compound classified as a psychotropic agent within the broader pharmacological group of antidepressants. Mirtazapine is more precisely designated as a Noradrenergic and Specific Serotonergic Antidepressant, or NaSSA. This specific classification is clinically recognized for identifying agents with a distinct dual mechanism of action on central nervous system chemistry. The drug is exclusively a single-ingredient product and is available only by prescription.

Composition, Forms, and General Therapeutic Role

Mirtazapine is prepared for oral administration and is supplied in the solid dosage forms of a standard film-coated tablet and an Oral Disintegrating Tablet (ODT). The ODT form, which dissolves rapidly without water, is a distinctive feature. The core purpose of Mirtazapine is to re-establish a more optimal chemical balance in the brain. Its primary function is to provide foundational support to neural communication, which aids in the stabilization of emotional well-being by acting on specific neurotransmitter systems.

Understanding Mirtazapine’s Unique Mechanism Profile

Mirtazapine’s action is defined by two principal properties: it enhances the release of the key neurotransmitters norepinephrine and serotonin, and it modulates specific receptor sites by acting as an antagonist at alpha2-adrenergic autoreceptors and 5-HT2 and 5-HT3 receptors. This integrated approach of boosting and refining chemical signaling is the high-level principle behind its supportive action in managing emotional equilibrium.

What side effects are possible with Remeron?

Possible Side Effects and Safety Information

The safety profile of Remeron (Mirtazapine) is formally classified by government regulatory authorities based on the frequency of adverse reactions observed in clinical trials and post-marketing surveillance.

Frequency-Classified Adverse Reactions

The official labeling organizes adverse effects into frequency categories, with the following being classified as Very Common (ge 10%) in regulatory documents:

  • Somnolence/Drowsiness
  • Increased Appetite
  • Weight Gain
  • Dry Mouth

Other frequently documented effects, classified as Common (1-10%), include dizziness, asthenia (lack of energy), confusion, anxiety, insomnia, constipation, and orthostatic hypotension (low blood pressure upon standing).

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile highlights risks considered to be clinically significant. These include the potential for Agranulocytosis (a severe reduction in white blood cells), which has been reported in post-marketing experience. The risk of Serotonin Syndrome is noted, particularly when the medicine is used concomitantly with other serotonergic agents. QT Prolongation and subsequent ventricular arrhythmia (Torsades de Pointes) are also documented as serious concerns.

Treatment is officially contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). Furthermore, regulatory instructions state that treatment must be discontinued immediately if signs of jaundice or seizures develop or if blood counts indicate bone marrow depression.

Population and Time-Related Safety Patterns

The safety of Mirtazapine is not established in the pediatric population (le 18 years), with an associated increase in suicide-related behaviors observed in trials for this age group. Reduced clearance is noted in older adults and those with renal or hepatic impairment. Certain effects, such as sedation and akathisia, are officially documented as being more likely to occur during the first few weeks of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define Mirtazapine (Remeron) overdose based on documented manifestations that may necessitate immediate medical intervention. Overdose may present with central nervous system (CNS) effects, including drowsiness, disorientation, impaired memory, and confusion. A rapid heart rate (tachycardia) has also been reported in association with overdose scenarios.

Documented Severe Outcomes and Required Actions

Serious outcomes, including fatalities, have been reported at higher than recommended dosages, particularly in mixed overdoses involving co-ingestion with other agents. Documented life-threatening complications include Serotonin Syndrome, a serious systemic toxicity, and significant cardiac abnormalities such as QT prolongation and Torsades de Pointes.

Regulatory guidance states that if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened, emergency services (911) must be called immediately. For any suspected overdose, the poison control helpline should be contacted. Management is focused on symptomatic and supportive treatment, as no specific antidote is known.

Therapeutic Uses of Remeron

Quick Facts: Uses of Remeron

  • Addresses symptoms of Major Depressive Disorder (MDD).
  • May offer support for mood symptoms, including persistent depressed mood.
  • Assists in managing associated symptoms such as loss of interest or pleasure in daily activities.
  • Aids in the resolution of emotional and physical symptoms of depression.

What Remeron Treats: Main Uses and Benefits

Remeron (mirtazapine) is a medication that healthcare providers may prescribe to help manage the symptoms of Major Depressive Disorder (MDD) in adults. The drug is primarily indicated for use in this therapeutic domain.

Its function is to support a resolution of the key emotional and physical manifestations of depression. In this role, it may assist in addressing symptoms such as a persistently low or sad mood, which is a core feature of the condition.

The medication also works to help manage several associated symptoms. These may include a diminished interest or pleasure in usual activities and other daily functional difficulties. Furthermore, it can contribute to a reduction in the overall severity of a major depressive episode. Patients may find that it offers support for improved sleep and an increased appetite, which are commonly disrupted by depression.

Eligibility and Restrictions for Use

The official regulatory documents establish strict eligibility criteria for the use of Remeron (mirtazapine), defining which populations are approved, restricted, or prohibited from use.

Contraindications and Age Restrictions

Category Eligibility Rule Status
Monoamine Oxidase Inhibitors (MAOIs) Concomitant use with MAOIs (including linezolid) or within 14 days of stopping an MAOI. Contraindicated
Hypersensitivity Known allergy to mirtazapine or any excipients. Contraindicated
Pediatric Use Individuals under 18 years of age. Not Approved

Conditional Use and Special Populations

Remeron is approved only for use in adults (18 years and older) for Major Depressive Disorder. For several patient groups, the label mandates caution due to potential changes in drug clearance or pre-existing conditions.

  • Impaired Organ Function: Caution is required, and a dose decrease may be needed, for patients with moderate to severe renal (kidney) or hepatic (liver) impairment.
  • Geriatric Patients: Use requires caution, as older adults may experience reduced drug clearance.
  • Pregnancy/Lactation: Use during pregnancy is advised only if clearly needed. For lactation, a decision must be made to discontinue either nursing or the drug, as mirtazapine is present in human milk.
  • Comorbid Conditions: Caution is advised in patients with a history of seizures or mania/hypomania (patients should be screened for bipolar disorder prior to use).

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of mirtazapine (Remeron) is defined by pharmacokinetic and pharmacodynamic mechanisms as documented in regulatory sources.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, is formally contraindicated. This restriction is due to the documented risk of Serotonin Syndrome. A mandatory 14-day separation period is required before starting or stopping mirtazapine when an MAOI is involved.

Drug-Drug and Substance Interactions

Interactions with substances that affect the CYP450 enzyme system modify mirtazapine exposure. Strong CYP3A inducers (e.g., carbamazepine) formally decrease mirtazapine plasma concentration, while strong CYP3A inhibitors (e.g., ketoconazole) increase it. Furthermore, mirtazapine has additive effects with certain substance classes.

Interaction Type Interacting Substance Examples Regulatory Outcome
Pharmacodynamic Other serotonergic drugs (Triptans, SSRIs), St. John's wort Increased risk of Serotonin Syndrome
CNS Depression Alcohol (ethanol), Benzodiazepines Additive sedating effects

Official labeling also advises that co-administration with Warfarin necessitates the monitoring of International Normalized Ratio (INR). In populations with hepatic or renal impairment, mirtazapine clearance is reduced, which formally increases systemic exposure.

Mechanism of Action

u1F52C How Remeron Works: Mechanism of Action

Disinhibition to Enhance Norepinephrine and Serotonin Release

Mirtazapine achieves its core action by blocking presynaptic alpha2-adrenergic receptors, which normally serve as an inhibitory feedback mechanism on neurons. By removing this mechanism, the drug effectively disinhibits the release of the key neurotransmitters Norepinephrine ( NE) and Serotonin ( 5-HT), increasing their availability in the synaptic cleft. This foundational mechanism increases the functional availability of NE and 5-HT for synaptic transmission.

Selective Filtering of Serotonergic Signaling

Concurrently, the drug acts as an antagonist at specific Serotonin receptors, 5-HT2 and 5-HT3. This action selectively refines the enhanced Serotonin signal, channeling the increased neurotransmitter activity primarily toward 5-HT1 receptor pathways. The 5-HT2 and 5-HT3 receptor antagonism refines the Serotonin signal profile.

Strong Central Histaminergic Suppression

A final key domain involves the drug's high-affinity antagonism of central Histamine H1 receptors, which are crucial for maintaining central arousal. This antagonism directly suppresses the histaminergic wakefulness system, resulting in a rapid physiological effect on the brain’s state of alertness.

Dosage and Administration Information

Official Administration and Dosage Guidelines

Remeron (mirtazapine) must be used strictly according to official prescribing instructions. The drug is exclusively for oral administration.


Dosage Forms and Standard Regimen

Property Official Instruction
Available Forms Film-coated tablets (7.5 mg, 15 mg, 30 mg, 45 mg) and Oral Disintegrating Tablets (ODT) (15 mg, 30 mg, 45 mg).
Starting Dose 15 mg once daily for adults.
Maintenance Dose Typically between 15 mg and 45 mg daily.
Maximum Dose 45 mg per day.

Dosing Schedule and Timing

Mirtazapine is usually taken once daily, preferably in the evening before sleep due to common sedative effects. While the dose may be taken with or without food, adjustments to the dosage should not be made more frequently than every one to two weeks to allow for the drug to reach a consistent effect.


Administration Specifics

  • Standard Tablets: Must be swallowed whole with fluid; they should not be chewed.
  • Oral Disintegrating Tablets (ODT): Should be placed on the tongue to dissolve rapidly in saliva. ODTs must be handled with dry hands and should not be split or broken.

Population-Specific Use

For older adults, the dosing range is the same as for adults, but initiation at a lower dose (e.g., 7.5 mg/day) may be considered, and increases must be closely monitored. Doses may also require reduction in patients with moderate to severe hepatic or renal impairment. The drug is not approved for use in individuals under 18 years of age.

Treatment Protocol

Standard protocols state that treatment should continue for at least six months after symptoms have resolved. Upon conclusion of therapy, the dose must be gradually reduced to avoid procedural constraints related to abrupt cessation.

Recent Clinical Evidence

Research evidence / Overview of studies for Remeron (Mirtazapine)


Evidence for the Acute Treatment of Major Depressive Disorder (MDD)

The primary research base for Mirtazapine was established by examining its use in adult patients with Major Depressive Disorder (MDD). This evidence comes mainly from short-term, placebo-controlled, double-blind Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, typically lasting between four and eight weeks. The trials monitored adult outpatients diagnosed with MDD, focusing on outcomes reflecting daily functioning or activity level, such as measuring changes in standardized depression symptom severity scales.

Studies monitored how symptoms evolved in the observed populations, and research describes patterns of measured difference when comparing groups who received Mirtazapine to those who received a placebo. However, the existing studies provide limited insight into long-term changes. The follow-up durations were limited primarily to the acute phase of treatment.


️ Evidence for Relapse Prevention and Sustained Response

Research has also explored the long-term pattern of Mirtazapine for patients who initially responded to treatment to assess sustained symptom levels. These studies were conducted using continuation trials, where adults were monitored for many months. The studies monitored the rates at which the pre-defined return of symptoms occurred (relapse). Findings describe patterns observed in the studies, where a difference was measured in the rates of depressive relapse when comparing patients who continued Mirtazapine to those who stopped treatment. Evidence contributes to the broader evidence landscape by monitoring symptom control after an episode.

It is important to note that this research mainly examined the prevention of a relapse of the same episode. Data for the prevention of a recurrence—a completely new episode after full recovery—are still emerging and are not fully established. Long-term effects are not fully established, as follow-up durations were limited to a fixed period of usually under one year.


Evidence for Use as an Augmentation Strategy

Mirtazapine was studied as an augmentation strategy—meaning research examined the addition of Mirtazapine to an existing single antidepressant in patients whose MDD symptoms were defined as an inadequate response to one medication alone. However, the findings were mixed across the available trials. Some research highlights changes measured during the study period, while other large studies did not report a statistically significant difference in symptom scale scores between the Mirtazapine augmentation and placebo augmentation groups. This uncertainty remains high, as comparative evidence is lacking and subgroup findings are uncertain.

Key Studies & References

  1. Mirtazapine - StatPearls - NCBI Bookshelf - NIH (General Overview of Clinical Use and Indications)

Frequently Asked Questions (FAQ)

Common questions about Remeron (FAQ)


Q: How quickly does Remeron typically start to work for its main uses?

According to official product information and clinical experience, some patients may notice initial changes, such as improvements in sleep or anxiety, within the first week. The full therapeutic effect may be observed over a period of about two to four weeks.


Q: What is the general experience of people starting Remeron?

The official safety profile indicates that the most commonly reported experiences when starting this medicine include drowsiness, increased appetite, and weight gain. These effects, especially sedation, may be more noticeable during the first few weeks of treatment.


Q: Are there specific warnings about driving or operating machinery while on Remeron?

Official labeling includes a warning regarding the need for caution when performing activities that demand mental alertness, such as driving or operating hazardous machinery. This caution is necessary because common side effects, like drowsiness and dizziness, may affect concentration.


Q: Are there any known issues with taking Remeron and certain pain relievers?

Regulatory documents warn that taking Remeron with other serotonergic drugs—a group that includes other serotonergic drugs—is associated with the risk of Serotonin Syndrome. This interaction is noted as a precaution.


Q: Is there a Black Box Warning associated with Remeron, and what does it concern?

Yes, Remeron does carry a Boxed Warning in its official labeling. This warning concerns the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) when treatment is first started.


Q: How should missed doses of Remeron generally be handled?

Official patient information describes that a forgotten dose should generally be skipped, and the next dose taken at the regular time. The instructions state not to take a double dose to compensate for the missed one.


Q: Can Remeron affect blood sugar levels?

Regulatory sources indicate that Mirtazapine may make it more difficult to keep blood sugar stable in patients with diabetes. Therefore, official sources indicate that monitoring of blood sugar may be warranted.


Q: How long after stopping Remeron do its effects typically clear the body?

The drug's elimination half-life (the time it takes for half the drug to leave the body) is typically 20 to 40 hours in healthy adults. Based on the half-life, the medicine is mostly eliminated from the body within several days after the last dose.


Q: Does Remeron have an effect on cholesterol levels?

Yes, elevated total cholesterol and triglyceride levels have been reported with mirtazapine use.


Q: What is the meaning of the half-life of Remeron?

The half-life, which is typically 20 to 40 hours for Remeron, is a measure used in medicine. It defines the time required for the amount of medicine in the body to be reduced by precisely one-half.


Q: Do studies suggest any specific genetic factors influence the response to Remeron?

Pharmacokinetic studies have shown that different pathways are involved in the drug's metabolism. Official information indicates that genetic differences do not significantly affect the way the drug is eliminated.


Q: Can Remeron affect sexual function?

While adverse reactions related to sexual function are not listed as common in clinical trials, post-marketing reports have documented sexual side effects.


Q: What is the difference between Remeron and other common antidepressants like SSRIs?

Remeron is classified as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). This means its mechanism works differently from agents like SSRIs, by enhancing the release of norepinephrine and serotonin while also blocking specific serotonin receptors.


Q: Are there any specific foods or drinks that should be avoided while taking Remeron?

Official interaction warnings specifically list alcohol (ethanol) due to the risk of additive sedating effects. Regulatory documents do not provide specific avoidance lists for non-alcoholic foods or drinks.


Q: Can Remeron be used by older adults?

Yes, Remeron is approved for use in adults, including older adults. However, regulatory instructions describe the need for caution in this population, as older adults may experience reduced clearance of the drug, sometimes necessitating a lower starting dose.


Q: Is there information about how Remeron might affect sleep?

Remeron is known for its strong effect on histamine receptors, which contributes to its sedating properties. Due to this effect, it is often taken in the evening. However, insomnia is also listed as a less frequent, but still common, side effect.


Q: Does Remeron have a risk of dependence or withdrawal symptoms?

The label describes that when discontinuing treatment, the dose should be gradually reduced to manage procedural constraints related to abrupt cessation. Official documentation does not describe the drug as having a risk of dependence or addiction.


Q: What is the longest period of time Remeron has been studied for use?

The longest period of study is often explored in continuation trials which examine relapse prevention. Research has monitored patients for many months, typically for fixed periods of under one year, following an initial response to treatment.


Q: Does Remeron affect liver function?

The official label describes that dose reductions may be needed for patients with moderate to severe hepatic (liver) impairment. Furthermore, the drug is required to be discontinued immediately if signs of jaundice (yellowing of the skin or eyes) develop.


Q: Is Remeron known to interact with herbal supplements?

Regulatory warnings specifically include the herbal supplement St. John's wort in the list of substances that increase the risk of Serotonin Syndrome when taken with Remeron. Official warnings are specific to this substance.


Q: What is the consensus in research about Remeron's effectiveness?

Research consists of short-term trials that explored changes in depressive symptoms when compared to placebo. Continuation trials have also monitored long-term symptom levels to assess relapse prevention. Findings on its use as an augmentation strategy (with other antidepressants) have been mixed.


Q: Are skin rashes or allergic reactions listed as possible side effects of Remeron?

Known hypersensitivity (allergic reactions) to the drug is listed as a contraindication to use. Skin rashes specifically are not listed among the most common adverse reactions in the official safety profile.


Q: What kind of monitoring is typically done when a person is on Remeron?

The label describes that specific monitoring is required for certain situations, such as checking International Normalized Ratio (INR) if taken with Warfarin. Blood cell counts are also a required form of monitoring if the patient develops signs of bone marrow depression.


Q: What distinguishes Remeron from SNRIs?

Remeron is a NaSSA, which is a different classification than an SNRI (Serotonin and Norepinephrine Reuptake Inhibitor). Its mechanism involves blocking specific alpha2 receptors and serotonin receptors to modulate and enhance neurotransmitter release, rather than primarily blocking reuptake.


Q: Is it common for Remeron to be used alongside other medications?

Official drug interaction profiles include many substances, such as benzodiazepines, which have additive sedating effects. Research has also explored its use as an augmentation strategy—the addition of Remeron to another antidepressant—in specific patient populations.


Q: Is Remeron used to help with sleep alone, or only as part of depression treatment?

Remeron is officially approved for the treatment of Major Depressive Disorder (MDD). Although it has a strong sedating effect and is often taken in the evening, the official therapeutic purpose is to provide support for balanced mood and emotional stability in the context of MDD.


Q: Is there a risk of high blood pressure when combining Remeron with other medications?

The official side effect profile lists orthostatic hypotension (a drop in blood pressure when standing) as a common effect. Regulatory documents do not generally mention a risk of high blood pressure (hypertension) for this drug, either alone or in combination.


Q: What should be done if a potential side effect is noticed while taking Remeron?

The official safety constraints provide specific, mandatory instructions for immediate discontinuation if serious reactions like jaundice, seizures, or signs of bone marrow depression occur. For managing other common or potential effects, the label does not provide general instructions.

How should Remeron be stored and disposed of?

How to Store and Dispose of Remeron (Mirtazapine)

The official labeling for Remeron (mirtazapine) mandates specific conditions for storage and disposal to ensure product integrity.


Required Storage Conditions

Requirement Specifics Based on Regulatory Labeling
Temperature Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Protection Must be protected from light and moisture.
Packaging Standard tablets must be stored in the original container.
Child Safety Keep out of the reach of children.

Stability and Disposal Rules

RemeronSolTab (orally disintegrating tablets) must remain in the blister pack and be used immediately after the individual blister is opened. Any unused or expired Remeron should be disposed of according to local regulatory requirements for pharmaceutical waste, as instructed by the manufacturer and government health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Remeron found in:

A-Z Index: